サンプル依頼リスト カート
  • English
  • Korean
市場調査レポート
商品コード
1650993

CAR T細胞療法の世界市場

CAR T-cell Therapy

出版日
ページ情報
英文 179 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
CAR T細胞療法の世界市場
出版日: 2025年02月07日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 179 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

CAR T細胞療法の世界市場は2030年までに米国で108億米ドルに達する見込み

2024年に33億米ドルと推定されるCAR T細胞療法の世界市場は、2024～2030年の分析期間においてCAGR 22.0%で成長し、2030年には108億米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるDLBCL適応症は、CAGR 18.6%を記録し、分析期間終了時には51億米ドルに達すると予測されます。ALL適応症の成長率は、分析期間中CAGR 25.4%と推定されます。

米国市場は9億4,400万米ドルと推定、中国はCAGR 21.4％で成長すると予測

米国のCAR T細胞療法市場は、2024年に9億4,400万米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに17億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは21.4%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ18.8%と18.6%と予測されています。欧州では、ドイツがCAGR約15.1%で成長すると予測されています。

世界のCAR T細胞療法市場- 主要動向と促進要因まとめ

CAR T細胞療法ががん治療のブレークスルーとなる理由とは？

キメラ抗原受容体（CAR）T細胞療法は、特に化学療法や放射線療法のような従来の治療法に反応しなかった特定のタイプの血液がんと闘う患者にとって、がん治療の展望に革命をもたらしました。この免疫療法は、がん細胞を標的として破壊するために、身体自身の免疫システムを利用し、強化することによって機能します。そのプロセスは、まず患者のT細胞（免疫反応に重要な白血球の一種）を採取することから始まる。次に、これらのT細胞は、がん細胞の表面にある特定のタンパク質を認識する受容体（CAR）を発現するように、実験室で遺伝子改変されます。T細胞が改変され増殖すると、患者の体内に再注入され、そこで驚異的な精度でがん細胞を探し出し破壊します。CAR T細胞療法は、特にB細胞リンパ腫や急性リンパ芽球性白血病（ALL）などの血液がんの治療において、顕著な効果を示しました。多くの場合、他の治療法をすべて使い果たした患者が長期間の寛解を経験しています。この治療法は個別化医療における大きな飛躍を意味します。というのも、この治療法は個人のがんプロファイルに合わせたものであり、腫瘍学に変革をもたらすオーダーメイドのアプローチを提供するものだからです。

技術革新はどのようにCAR T細胞療法の有効性を高めているのか？

CAR T細胞療法の開発は、治療の有効性と安全性プロファイルの両方を向上させる最先端技術によって大きく前進しました。最も重要な技術革新のひとつは、より洗練されたCARコンストラクトの設計であり、がん細胞をより正確に標的とすることができるようになりました。初期のCAR T細胞療法は、がん細胞上の単一の抗原を標的としていたが、新しいバージョンは複数の抗原を認識するように設計されており、がんが検出を逃れる可能性を減らしています。これは、がん細胞が免疫破壊を避けるために変異する抗原逃避のような課題に対処する上で特に重要です。さらに、CRISPRのような遺伝子編集技術の進歩により、科学者たちはT細胞をより正確に改変することができるようになり、がん細胞を標的とする能力を高めると同時に、健康な組織への意図しない影響のリスクを減らすことができるようになった。細胞製造プロセスの技術的改善により、T細胞の改変と増殖に必要な時間も短縮され、この治療法はより利用しやすくなり、侵攻性のがん患者の待ち時間も短縮されました。さらに、人工知能（AI）と機械学習がCAR T細胞療法の開発と投与に統合されたことで、研究者と臨床医は患者の反応をより正確に予測できるようになり、治療プロセスが最適化されました。これらの技術革新は、CAR T細胞療法の有効性を高めるだけでなく、この強力な治療法が世界中のより多くの患者に利用されることを保証する、その拡張性にも貢献しています。

CAR T細胞療法の現在の動向と課題は？

いくつかの重要な動向がCAR T細胞療法の将来を形成しており、その将来性と潜在能力を最大限に引き出すために対処すべき課題の両方を反映しています。最もエキサイティングな動向の一つは、CAR T細胞療法が血液がんだけでなく、固形がんにも拡大しつつあることです。歴史的に、固形がんの治療は、免疫細胞が侵入して攻撃することを困難にする、腫瘍自身の周囲に形成される保護環境のために、より複雑でした。しかし、固形腫瘍へのT細胞浸潤を促進し、敵対的な腫瘍微小環境においてもその活性を持続させる方法が、積極的に研究されています。もう一つの重要な動向は、同種または"既製"のCAR T細胞療法の開発です。患者自身の細胞を取り出し、改変する必要がある従来のアプローチ（自己細胞療法）とは異なり、同種療法では健康なドナーから採取したT細胞を用います。このアプローチにより、治療にかかる時間とコストが大幅に削減され、より広く利用できるようになる可能性があります。このような進歩にもかかわらず、いくつかの課題が残っています。サイトカイン放出症候群（CRS）や神経毒性などの重篤な副作用の管理は、依然として重大な懸念事項です。これらの副作用は、治療によって免疫系が過剰に活性化され、炎症や潜在的に危険な合併症を引き起こすことによって起こる。研究はこれらのリスクを軽減することに重点を置いており、緊急時にCAR T細胞を不活性化する内蔵の「自殺スイッチ」など、いくつかの安全メカニズムが開発されています。さらに、CAR T細胞療法の製造コストが高く、患者一人当たり数十万米ドルを超えることが多いことも、より広範な採用を阻む大きな障壁となっています。このコストは、個別化された生きた細胞治療の製造の複雑さを反映しているが、コスト削減のため、製造の合理化やより効率的な製造技術の開発が進められています。

CAR T細胞療法市場の成長の原動力は？

CAR T細胞療法市場の成長は、技術の進歩、臨床適応の拡大、個別化がん治療に対する需要の増加など、いくつかの要因によってもたらされます。主な促進要因の一つは、様々なタイプのがん、特にリンパ腫、白血病、多発性骨髄腫などの血液悪性腫瘍の治療におけるCAR T細胞療法の有効性を実証する臨床エビデンスの拡大です。CAR T細胞療法が固形がんの治療に進出する可能性は、肺がん、乳がん、膵臓がんのようながんにおける新たな治療標的や応用について継続的に調査が行われていることから、もう一つの重要な成長機会となります。遺伝子編集ツールや細胞製造プロセスの技術的向上も市場の成長に寄与しており、CAR T細胞をより迅速かつコスト効率よく製造できるようになっています。個別化医療に対する需要の高まりも、市場拡大を後押しする重要な要因のひとつです。患者やヘルスケアプロバイダーは、個々のがん特有の遺伝的・分子的プロファイルに合わせた治療を求めているからです。これは、従来の治療法が失敗した場合に特に重要であり、CAR T細胞療法は代替手段の少ない患者にとって不可欠な選択肢となっています。加えて、世界のがん罹患率の増加は、特に欧州やアジアなどCAR T細胞療法の承認が拡大している地域において、より革新的な治療に対する需要を煽っています。より安価で広く利用可能な治療選択肢を提供しうる同種CAR T細胞療法の開発は、市場の成長をさらに加速させる。治療精度とモニタリングを向上させるAIの絶え間ない進歩と、患者の転帰を向上させることへの注目の高まりにより、CAR T細胞療法市場は今後数年間で力強い成長が見込まれます。

セグメント

適応症（DLBCL、ALL、MM、CLL、FL）

調査対象企業の例（注目12社）

  • A2 Biotherapeutics, Inc.
  • Adaptive Biotechnologies Corporation
  • Advanced Cell & Gene Therapy
  • AffyImmune Therapeutics
  • Allogene Therapeutics
  • Beam Therapeutics
  • CARsgen Therapeutics
  • Celgene Corporation
  • Cellular Biomedicine Group, Inc.
  • Innovacell

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • その他欧州
  • アジア太平洋
  • その他の地域

第4章 競合

目次
Product Code: MCP10884

Global CAR T-cell Therapy Market to Reach US$10.8 Billion by 2030

The global market for CAR T-cell Therapy estimated at US$3.3 Billion in the year 2024, is expected to reach US$10.8 Billion by 2030, growing at a CAGR of 22.0% over the analysis period 2024-2030. DLBCL Indication, one of the segments analyzed in the report, is expected to record a 18.6% CAGR and reach US$5.1 Billion by the end of the analysis period. Growth in the ALL Indication segment is estimated at 25.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$944.0 Million While China is Forecast to Grow at 21.4% CAGR

The CAR T-cell Therapy market in the U.S. is estimated at US$944.0 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.7 Billion by the year 2030 trailing a CAGR of 21.4% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 18.8% and 18.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 15.1% CAGR.

Global CAR T-cell Therapy Market - Key Trends and Drivers Summarized

What Makes CAR T-Cell Therapy a Breakthrough in Cancer Treatment?

Chimeric Antigen Receptor (CAR) T-cell therapy has revolutionized the landscape of cancer treatment, particularly for patients battling certain types of blood cancers that have not responded to conventional therapies like chemotherapy and radiation. This form of immunotherapy works by harnessing and enhancing the body's own immune system to target and destroy cancer cells. The process begins with the extraction of a patient’s T-cells, a type of white blood cell crucial to immune response. These T-cells are then genetically modified in a laboratory to express a receptor (CAR) that allows them to recognize specific proteins on the surface of cancer cells. Once the T-cells are modified and multiplied, they are reinfused into the patient’s body, where they seek out and destroy the cancer cells with extraordinary precision. CAR T-cell therapy has shown remarkable efficacy, particularly in treating hematologic cancers such as B-cell lymphomas and acute lymphoblastic leukemia (ALL). In many cases, patients who had exhausted all other treatment options have experienced long-term remission. This therapy represents a significant leap forward in personalized medicine, as it is tailored to the individual’s specific cancer profile, offering a customized approach that has been transformative in oncology.

How Are Technological Innovations Enhancing the Efficacy of CAR T-Cell Therapy?

The development of CAR T-cell therapy has been significantly advanced by cutting-edge technologies that have improved both the efficacy of the treatment and its safety profile. One of the most critical innovations has been the design of more sophisticated CAR constructs, allowing for greater precision in targeting cancer cells. Early iterations of CAR T-cell therapy targeted a single antigen on cancer cells, but newer versions are engineered to recognize multiple antigens, reducing the chances of the cancer evading detection. This has been especially important in addressing challenges like antigen escape, where cancer cells mutate to avoid immune destruction. In addition, advancements in gene-editing technologies, such as CRISPR, have enabled scientists to modify T-cells with increased accuracy, enhancing their ability to target cancer cells while reducing the risk of unintended effects on healthy tissues. Technological improvements in cell manufacturing processes have also reduced the time needed to modify and expand T-cells, making the therapy more accessible and reducing wait times for patients with aggressive cancers. Furthermore, the integration of artificial intelligence (AI) and machine learning into the development and administration of CAR T-cell therapy has enabled researchers and clinicians to predict patient responses more accurately, optimizing the treatment process. These innovations not only enhance the effectiveness of CAR T-cell therapy but also contribute to its scalability, ensuring that this powerful treatment is available to a broader range of patients worldwide.

What Are the Current Trends and Challenges in CAR T-Cell Therapy?

Several important trends are shaping the future of CAR T-cell therapy, reflecting both its promise and the challenges that must be addressed to maximize its potential. One of the most exciting trends is the expansion of CAR T-cell therapy beyond blood cancers to solid tumors. Historically, treating solid tumors has been more complex due to the protective environment these tumors create around themselves, making it difficult for immune cells to penetrate and attack. However, research is actively exploring ways to enhance T-cell infiltration into solid tumors and sustain their activity in the hostile tumor microenvironment. Another significant trend is the development of allogeneic, or "off-the-shelf," CAR T-cell therapies. Unlike the traditional approach that requires extracting and modifying a patient’s own cells (autologous therapy), allogeneic CAR T-cell therapy uses T-cells from healthy donors. This approach promises to significantly reduce the time and cost associated with the therapy, potentially making it more widely accessible. Despite these advancements, several challenges remain. Managing severe side effects, such as cytokine release syndrome (CRS) and neurotoxicity, remains a critical concern. These side effects occur when the immune system is over-activated by the therapy, causing inflammation and potentially dangerous complications. Research is focused on mitigating these risks, and several safety mechanisms, including built-in "suicide switches" that deactivate the CAR T-cells in emergencies, are being developed. Additionally, the high cost of manufacturing CAR T-cell therapy, often exceeding several hundred thousand dollars per patient, is a major barrier to broader adoption. This cost reflects the complexity of producing a personalized, living cell therapy, but efforts to streamline production and develop more efficient manufacturing techniques are underway to reduce costs.

What’s Driving Growth in the CAR T-Cell Therapy Market?

The growth in the CAR T-cell therapy market is driven by several factors, including technological advancements, expanding clinical indications, and the increasing demand for personalized cancer treatments. One of the primary drivers is the expanding body of clinical evidence demonstrating the efficacy of CAR T-cell therapy in treating various types of cancer, especially hematologic malignancies such as lymphoma, leukemia, and multiple myeloma. The potential for CAR T-cell therapy to move into the treatment of solid tumors represents another key growth opportunity, as ongoing research continues to investigate new therapeutic targets and applications in cancers like lung, breast, and pancreatic cancer. Technological improvements in gene-editing tools and cell manufacturing processes are also contributing to the market’s growth, allowing for faster and more cost-effective production of CAR T-cells. The increasing demand for personalized medicine is another crucial factor driving market expansion, as patients and healthcare providers look for treatments tailored to the unique genetic and molecular profile of individual cancers. This is especially important in cases where traditional therapies have failed, making CAR T-cell therapy a vital option for those with few alternatives. Additionally, the global rise in cancer prevalence is fueling demand for more innovative treatments, particularly in regions where regulatory approvals for CAR T-cell therapies are expanding, such as in Europe and Asia. The development of allogeneic CAR T-cell therapies, which could provide more affordable and widely available treatment options, further accelerates market growth. With continuous advancements in AI, which are improving treatment precision and monitoring, and the growing focus on enhancing patient outcomes, the CAR T-cell therapy market is positioned for robust growth in the years to come.

SCOPE OF STUDY:

The report analyzes the CAR T-cell Therapy market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Indication (DLBCL, ALL, MM, CLL, FL)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 12 Featured) -

  • A2 Biotherapeutics, Inc.
  • Adaptive Biotechnologies Corporation
  • Advanced Cell & Gene Therapy
  • AffyImmune Therapeutics
  • Allogene Therapeutics
  • Beam Therapeutics
  • CARsgen Therapeutics
  • Celgene Corporation
  • Cellular Biomedicine Group, Inc.
  • Innovacell

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • CAR T-cell Therapy - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Incidence of Cancer Throws the Spotlight on CAR T-Cell Therapy as a Key Treatment Option
    • Technological Advancements in Gene Editing Propel Growth in CAR T-Cell Therapy Efficacy and Safety
    • Expanding Clinical Applications Beyond Blood Cancers Expands Addressable Market Opportunity
    • Here's How Personalized Medicine Strengthens the Business Case for CAR T-Cell Therapy
    • Increased Research on Solid Tumor Applications Spurs Growth in CAR T-Cell Therapy Development
    • Allogeneic 'Off-the-Shelf' CAR T-Cell Therapies Generate New Opportunities in Manufacturing
    • Emerging Strategies to Combat Cytokine Release Syndrome Expands the Safety Profile of CAR T-Cell Therapy
    • Global Focus on Precision Oncology Expands the Market for CAR T-Cell Therapies
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World CAR T-cell Therapy Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for CAR T-cell Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World 6-Year Perspective for CAR T-cell Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2025 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for DLBCL by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 5: World 6-Year Perspective for DLBCL by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 6: World Recent Past, Current & Future Analysis for ALL by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 7: World 6-Year Perspective for ALL by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for MM by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World 6-Year Perspective for MM by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for CLL by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 11: World 6-Year Perspective for CLL by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 12: World Recent Past, Current & Future Analysis for FL by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 13: World 6-Year Perspective for FL by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • CAR T-cell Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 14: USA Recent Past, Current & Future Analysis for CAR T-cell Therapy by Indication - DLBCL, ALL, MM, CLL and FL - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 15: USA 6-Year Perspective for CAR T-cell Therapy by Indication - Percentage Breakdown of Value Sales for DLBCL, ALL, MM, CLL and FL for the Years 2025 & 2030
  • CANADA
    • TABLE 16: Canada Recent Past, Current & Future Analysis for CAR T-cell Therapy by Indication - DLBCL, ALL, MM, CLL and FL - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 17: Canada 6-Year Perspective for CAR T-cell Therapy by Indication - Percentage Breakdown of Value Sales for DLBCL, ALL, MM, CLL and FL for the Years 2025 & 2030
  • JAPAN
    • CAR T-cell Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 18: Japan Recent Past, Current & Future Analysis for CAR T-cell Therapy by Indication - DLBCL, ALL, MM, CLL and FL - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 19: Japan 6-Year Perspective for CAR T-cell Therapy by Indication - Percentage Breakdown of Value Sales for DLBCL, ALL, MM, CLL and FL for the Years 2025 & 2030
  • CHINA
    • CAR T-cell Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 20: China Recent Past, Current & Future Analysis for CAR T-cell Therapy by Indication - DLBCL, ALL, MM, CLL and FL - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 21: China 6-Year Perspective for CAR T-cell Therapy by Indication - Percentage Breakdown of Value Sales for DLBCL, ALL, MM, CLL and FL for the Years 2025 & 2030
  • EUROPE
    • CAR T-cell Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 22: Europe Recent Past, Current & Future Analysis for CAR T-cell Therapy by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 23: Europe 6-Year Perspective for CAR T-cell Therapy by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2025 & 2030
    • TABLE 24: Europe Recent Past, Current & Future Analysis for CAR T-cell Therapy by Indication - DLBCL, ALL, MM, CLL and FL - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 25: Europe 6-Year Perspective for CAR T-cell Therapy by Indication - Percentage Breakdown of Value Sales for DLBCL, ALL, MM, CLL and FL for the Years 2025 & 2030
  • FRANCE
    • CAR T-cell Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 26: France Recent Past, Current & Future Analysis for CAR T-cell Therapy by Indication - DLBCL, ALL, MM, CLL and FL - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 27: France 6-Year Perspective for CAR T-cell Therapy by Indication - Percentage Breakdown of Value Sales for DLBCL, ALL, MM, CLL and FL for the Years 2025 & 2030
  • GERMANY
    • CAR T-cell Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 28: Germany Recent Past, Current & Future Analysis for CAR T-cell Therapy by Indication - DLBCL, ALL, MM, CLL and FL - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 29: Germany 6-Year Perspective for CAR T-cell Therapy by Indication - Percentage Breakdown of Value Sales for DLBCL, ALL, MM, CLL and FL for the Years 2025 & 2030
  • ITALY
    • TABLE 30: Italy Recent Past, Current & Future Analysis for CAR T-cell Therapy by Indication - DLBCL, ALL, MM, CLL and FL - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 31: Italy 6-Year Perspective for CAR T-cell Therapy by Indication - Percentage Breakdown of Value Sales for DLBCL, ALL, MM, CLL and FL for the Years 2025 & 2030
  • UNITED KINGDOM
    • CAR T-cell Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 32: UK Recent Past, Current & Future Analysis for CAR T-cell Therapy by Indication - DLBCL, ALL, MM, CLL and FL - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: UK 6-Year Perspective for CAR T-cell Therapy by Indication - Percentage Breakdown of Value Sales for DLBCL, ALL, MM, CLL and FL for the Years 2025 & 2030
  • REST OF EUROPE
    • TABLE 34: Rest of Europe Recent Past, Current & Future Analysis for CAR T-cell Therapy by Indication - DLBCL, ALL, MM, CLL and FL - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 35: Rest of Europe 6-Year Perspective for CAR T-cell Therapy by Indication - Percentage Breakdown of Value Sales for DLBCL, ALL, MM, CLL and FL for the Years 2025 & 2030
  • ASIA-PACIFIC
    • CAR T-cell Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 36: Asia-Pacific Recent Past, Current & Future Analysis for CAR T-cell Therapy by Indication - DLBCL, ALL, MM, CLL and FL - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 37: Asia-Pacific 6-Year Perspective for CAR T-cell Therapy by Indication - Percentage Breakdown of Value Sales for DLBCL, ALL, MM, CLL and FL for the Years 2025 & 2030
  • REST OF WORLD
    • TABLE 38: Rest of World Recent Past, Current & Future Analysis for CAR T-cell Therapy by Indication - DLBCL, ALL, MM, CLL and FL - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Rest of World 6-Year Perspective for CAR T-cell Therapy by Indication - Percentage Breakdown of Value Sales for DLBCL, ALL, MM, CLL and FL for the Years 2025 & 2030

IV. COMPETITION